Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

Abstract: Assays (100) may be performed with a luminometer (400) having a chassis (405) that may include a reaction vessel chamber (610). The luminometer (400) may also include a light passage (640) that intersects the reaction vessel chamber (610). The luminometer (400) may also include a cap (415) that, when in a closed configuration, prevents light emitted by external sources from entering the reaction vessel chamber (610) and from entering the light passage (640). The cap (415) may provide access to the reaction vessel chamber (610) when in an open configuration. The luminometer (400) may also include a calibration light source (460) optically coupled to one end of the light passage (640) and a light detector (630) optically coupled to another end of the light passage (640). The light detector (630) may include a sensing element for receiving light from the light passage (640).

Abstract: A luminometer (400) includes a light detector (630) configured to sense photons (135). The luminometer (400) includes an analog circuit (915a) configured to provide an analog signal (965) based on the photons (135) emitted from assay reactions over a time period and a counter circuit (915b) configured to provide a photon count (970) based on the photons (135) emitted from the assay reactions over the time period. The luminometer (400) includes a luminometer controller (905) configured to, in response to an analog signal value of the analog signal (965) being greater than a predetermined value, determine and report a measurement value of the photons (135) emitted from the assay reactions over the time period based on the analog signal value of the analog signal (965) and a linear function (1010). Optionally, the linear function (1010) is derived from a relationship between the analog signal (965) and the photon count (970).

Abstract: Methods, systems, and computer-readable media for the generation of customizable insights using machine learning models. The method acquires data from one or more sources with different formats and data organization to extract events that each represent an interaction between a user and a service and classify the extracted events by adding labels to each of the extracted events. The method next projects the extracted events and generates the customized insights of events representing user interactions.

Abstract: Assays (100) may be performed with a luminometer (400) having a chassis (405) that may include a reaction vessel chamber (610). The luminometer (400) may also include a light passage (640) that intersects the reaction vessel chamber (610). The luminometer (400) may also include a cap (415) that, when in a closed configuration, prevents light emitted by external sources from entering the reaction vessel chamber (610) and from entering the light passage (640). The cap (415) may provide access to the reaction vessel chamber (610) when in an open configuration. The luminometer (400) may also include a calibration light source (460) optically coupled to one end of the light passage (640) and a light detector (630) optically coupled to another end of the light passage (640). The light detector (630) may include a sensing element for receiving light from the light passage (640).

Abstract: A luminometer (400) includes a light detector (630) configured to sense photons (135). The luminometer (400) includes an analog circuit (915a) configured to provide an analog signal (965) based on the photons (135) emitted from assay reactions over a time period and a counter circuit (915b) configured to provide a photon count (970) based on the photons (135) emitted from the assay reactions over the time period. The luminometer (400) includes a luminometer controller (905) configured to, in response to an analog signal value of the analog signal (965) being greater than a predetermined value, determine and report a measurement value of the photons (135) emitted from the assay reactions over the time period based on the analog signal value of the analog signal (965) and a linear function (1010). Optionally, the linear function (1010) is derived from a relationship between the analog signal (965) and the photon count (970).

Abstract: A luminometer (400) includes a light detector (630) configured to sense photons (135). The luminometer (400) includes an analog circuit (915a) configured to provide an analog signal (965) based on the photons (135) emitted from assay reactions over a time period and a counter circuit (915b) configured to provide a photon count (970) based on the photons (135) emitted from the assay reactions over the time period. The luminometer (400) includes a luminometer controller (905) configured to, in response to an analog signal value of the analog signal (965) being greater than a predetermined value, determine and report a measurement value of the photons (135) emitted from the assay reactions over the time period based on the analog signal value of the analog signal (965) and a linear function (1010). Optionally, the linear function (1010) is derived from a relationship between the analog signal (965) and the photon count (970).

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.

Abstract: The present invention relates to vesicular formulations for use in the topical administration of a therapeutic, metabolic, cosmetic or structural Agent Of Interest (“AOI”) and methods of administering an AOI.

Abstract: The present invention relates to vesicular formulations for use in the treatment of pain and/or reduced mobility associated with a loss of lubrication and/or structural integrity and/or swelling of a collagen structure. It also relates to a method of treating pain such as joint pain or tendonitis comprising topically administering a vesicular formulation according to the invention.

Abstract: The invention provides a composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.

Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: A luminometer (400) includes a light detector (630) configured to sense photons (135). The luminometer (400) includes an analog circuit (915a) configured to provide an analog signal (965) based on the photons (135) emitted from assay reactions over a time period and a counter circuit (915b) configured to provide a photon count (970) based on the photons (135) emitted from the assay reactions over the time period. The luminometer (400) includes a luminometer controller (905) configured to, in response to an analog signal value of the analog signal (965) being greater than a predetermined value, determine and report a measurement value of the photons (135) emitted from the assay reactions over the time period based on the analog signal value of the analog signal (965) and a linear function (1010). Optionally, the linear function (1010) is derived from a relationship between the analog signal (965) and the photon count (970).

Abstract: The present invention relates to compositions comprising a colloidal dispersion and an Agent of Interest (“AOI”), wherein the colloidal dispersion comprises deformable colloidal particles and wherein the AOI is not associated with the deformable colloidal particles. The present invention also provides kits and transdermal drug release devices comprising the compositions of the present invention, and the use of these compositions in medicine, skin care and cosmetics.

Abstract: Assays (100) may be performed with a luminometer (400) having a chassis (405) that may include a reaction vessel chamber (610). The luminometer (400) may also include a light passage (640) that intersects the reaction vessel chamber (610). The luminometer (400) may also include a cap (415) that, when in a closed configuration, prevents light emitted by external sources from entering the reaction vessel chamber (610) and from entering the light passage (640). The cap (415) may provide access to the reaction vessel chamber (610) when in an open configuration. The luminometer (400) may also include a calibration light source (460) optically coupled to one end of the light passage (640) and a light detector (630) optically coupled to another end of the light passage (640). The light detector (630) may include a sensing element for receiving light from the light passage (640).

Abstract: The invention provides a composition comprising a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for use in medicine, wherein said composition does not contain any pharmaceutically active agent.

Abstract: The present invention relates to a formulation comprising blends of formulations (or colloidal dispersions) and its topical application. The formulation comprises at least two different types of colloidal dispersion comprising deformable colloidal particles, wherein the deformable colloidal particles comprise a non-ionic surfactant and/or a phospholipid. The deformable colloidal particles of the invention may comprise an agent of interest (AOI) or may be free of an AOI. The formulation may comprise an AOI that is not associated with the deformable colloidal particles. The present invention also includes kits comprising the formulation of the present invention and the use of the formulation in medicine, skin care and cosmetics.